Skip to main content
OpenTrials
Completed

NCT Number: NCT05859958

ABO Blood Group Type Association With COVID-19 Severity

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

Early reports have indicated a significant relationship of ABO blood group types to the risk of infection with SARS-CoV-2. Specifically, the first systematic review and meta-analysis by Wu et al. in October 2020 cited that blood type A had increased risk for infection with SARS-CoV-2 and blood type O had decreased risk of infection. Another early meta-analysis by Zaidi et al. cited that blood type A had increased odds of infection, type O had decreased odds of infection, type AB had increased risk of disease severity, and type B had decreased risk of demise.

As more multi-national data became available, as a result of global concerted efforts, larger studies produced data to further investigate this connection. Overall, the majority of studies reproduced similar data: type O had decreased risk of infection with SARS-CoV-2, while type A had increased risk of infection. One study in the United Kingdom failed to produce a relationship between blood types and COVID-19. As more data became available, several studies were able to study the association of blood group type with mortality and disease severity; however, the data regarding this is inconsistent. Gutierrez-Valencia et al. did not find an association with blood types and ICU admission or mechanical ventilation; however, they did note an increased risk of mortality in blood type A. Liu et al. and Pereira et al. demonstrated that there is also increased risk of mortality in blood type A. Jerico et al. noted a lower risk for ICU admission in blood type O. Goel et al. noted an increased risk of disease severity in blood type A. As evident, it seems that blood type A has increased risk of mortality and, likely, disease severity.

In this study, we aim to evaluate association of blood types with mortality and disease severity at a county hospital in Southern California. We will review charts for patients infected with SARS-CoV-2 during a two-year time period, evaluating mortality, oxygen requirements, and patient historical factors. Through this study, we aim to gain a better understanding of how blood group types may affect patient outcomes in the setting of COVID-19.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • COVID-19 confirmed by laboratory testing (ICD10 U07.1)
  • Pneumonia due to COVID-19 (ICD10 J12.82)
  • Multisystem inflammatory syndrome from COVID in adults (ICD10 M35.81)
  • Adult respiratory distress syndrome (ICD10 J80)
  • Abnormal pulmonary function test (ICD10 R94.2)
  • Intensive care unit admission for COVID-19

Exclusion criteria

  • COVID-19 Diagnosis under 18 years of age
  • COVID in pregnancy (O98.52, O98.511, O98.512, O98.513, O98.519, O98.53)

Treatment and study plan

No intervention

Other

Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups

Primary outcomes

  1. Length of hospital stay

    Time frame: Length of total hospital stay from admission in the hospital is defined as the time frame between admission and discharge. The time frame of collection until the event occurred was 360 days.

    The time spent hospitalized in days.

  2. Hospital Mortality

    Time frame: 28 days

    Survival within the first 28 days

  3. Discharge disposition

    Time frame: 360 days

    Location of discharge after hospital course completed

Sponsors and collaborators

Lead sponsor

Arrowhead Regional Medical Center

Other

Registry information

Official study title

ABO Blood Group Type Association With COVID-19 Severity - A Single Center Study

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 16, 2023
Registry last updated
May 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.